Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 25, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 3,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,230.86 pence per share.
- Treasury Holdings: 465,114,158 shares (representing 8.37% of total voting rights).
- Shares in Issue: 5,559,791,462 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the purchase of 3,000,000 shares on October 25, 2007. This transaction reduces the number of shares available for trading in the open market and increases the percentage of voting rights held in Treasury to 8.37%.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure that the announcement does not constitute an offer to purchase securities. The transaction was executed in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 3,000,000 shares by the price of 1,230.86 pence.
- Confirm the updated total voting rights denominator (5,559,791,462 shares) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Note that the repurchased shares are held in Treasury and do not carry voting rights.
- Recognize that this filing is a notification of a specific transaction and does not contain periodic financial performance data.